UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
CHRIS WRIGHT, : : Plaintiff, : Civil Action No.: 22-1378 (RC) : v. : Re Document Nos.: 48, 52 : U.S. DEPARTMENT OF HEALTH : AND HUMAN SERVICES, : : Defendant. :
MEMORANDUM OPINION
GRANTING DEFENDANT’S MOTION TO EXTEND STAY; DENYING PLAINTIFF’S MOTION FOR ORDER
I. INTRODUCTION
In this Freedom of Information Act (“FOIA”) action, the U.S. Department of Health and
Human Services (“HHS” or “Defendant”), on behalf of the U.S. Food and Drug Administration
(“FDA” or the “Agency”), seeks to extend the existing stay of the FDA’s further response to the
FOIA request at issue for an additional six months. HHS argues that the FDA is entitled to a stay
because the FDA is under an extraordinary workload that could not have been predicted, and the
FDA has been exercising due diligence in responding to the orders. Proceeding pro se, plaintiff
Chris Wright (“Wright” or “Plaintiff”) contends that because HHS admitted wrongdoing and the
new administration’s attitude towards the public’s rights to public health information differ from
the previous administration, this Court should not grant HHS’s motion to extend stay.
Separately, Wright requested this Court to order President Donald J. Trump’s political
appointees to personally review this case and see whether they want to handle the case
differently than President Joseph R. Biden’s administration. HHS argues that Wright’s motion lacks basis and should be denied. For the foregoing reasons, the Court grants HHS’s motion to
extend stay and denies Wright’s motion for order.
II. FACTUAL AND PROCEDURAL BACKGROUND
A. Factual Background
This action stems from a FOIA request submitted by Wright on November 12, 2021,
seeking several categories of records related to adverse reactions to COVID-19 vaccines.
Specifically, Wright made four requests: (1) “[d]ecision memo(s) or other records regarding
further studies of [Vaccine Adverse Event Reporting System . . . ] COVID vaccine adverse
reaction reports, setting forth the decision(s) and underlying rationale(s)[,]” (2) “[a]ny and all
further studies of adverse reactions to COVID vaccines that have been conducted[,]” (3) “[a]ny
and all records discussing adverse reactions to COVID vaccines after the decision memo(s)[,]”
and (4) [a]ny and all records previously released under same or similar FOIA requests.” Def.’s
Statement of Material Facts Not in Genuine Dispute (“Def.’s Stmt.”) ¶ 1, ECF No. 38-1; Decl. of
Alesia Y. Williams (“Williams Decl.”), Ex. A, ECF No. 38-3. The CDC acknowledged the
request on November 16, 2021, and placed it in its complex processing queue. Def.’s Stmt.
¶¶ 2–3; Decl. of Roger Andoh (“Andoh Decl.”) ¶ 5, ECF No. 38-5. Wright then revised the third
item in the request to specifically target records analyzing mortality as a vaccine adverse
reaction, and he instructed the CDC to use search terms including “death,” “dying,” “dead,”
“kill,” and “murder,” among others. Def.’s Stmt. ¶ 4; Andoh Decl. ¶¶ 17–18.
Following this, the CDC searched records within its Immunization and Safety Office
(“ISO”) and determined the records requested fell within that office’s purview. Andoh Decl. ¶ 6.
The CDC explained that the ISO is responsible for monitoring vaccine safety and therefore was
the appropriate entity to conduct the search. See Def.’s Stmt. ¶ 5; Andoh Decl. ¶ 6. Regarding
2 Item 1, the CDC stated that it does not produce decision memos and therefore had no responsive
documents, but it provided links to standard operating procedures and vaccine safety studies.
See Andoh Decl. ¶ 11; Def.’s Stmt. ¶ 8. For Item 2, the CDC searched and shared links to all
publicly available COVID-19 studies. See Andoh Decl. ¶ 12; Def.’s Stmt. ¶ 8. Following the
revised request for Item 3, the CDC provided links to responsive public records using the
mortality-related search terms. See Andoh Decl. ¶ 19; Def.’s Stmt. ¶ 8. Finally, for Item 4, a
relevant CDC division searched the FOIA inbox, and the search produced thirteen responsive
documents, which were subsequently released to Wright. See Andoh Decl. ¶ 14; Def.’s Stmt.
¶ 8.
Wright then proceeded by filing a motion to compel in July 2023, and in response, the
CDC expanded its search related to Item 1. See Def.’s Stmt. ¶ 6; Andoh Decl. ¶¶ 23–24. From
the expanded search, thirteen pages were partially redacted, six pages were withheld entirely, and
the rest were released in full. Andoh Decl. ¶¶ 23–27; see also CDC Vaughn Index,
ECF No. 38-6. The CDC also asked the Chief Medical Officer and the Incident Manager of the
Coronavirus and Other Respiratory Viruses Division to search their emails and shared drives for
relevant documents, which did not result in any responsive records. Andoh Decl. ¶ 25; Def.’s
Stmt. ¶ 7.
In addition to the CDC’s efforts, HHS itself conducted a search through the Office of the
Chief Information Officer (“OCIO”) within the Office of the Secretary. Def.’s Stmt. ¶ 10;
Williams Decl. at 3, ECF No. 38-2. In response to Wright’s motion to compel, HHS identified
the OCIO as a potential source for responsive records. Id. On April 23, 2024, HHS directed the
OCIO to perform a search of the agency’s email enterprise for emails from key custodians:
Secretary Xavier Becerra, Deputy Secretary Andrea Palm, and Chief of Staff Sean McCluskie.
3 Williams Decl. at 3–4. These individuals were selected based on their likely involvement in
discussions regarding VAERS COVID vaccine adverse reaction reports. Id. ¶ 6. The search
used the terms “Proposal AND COVID AND VAERS” and was limited to emails from
December 14, 2020, through November 11, 2021, which aligned with the time frame specified in
Wright’s FOIA request. Id. ¶ 7. This search yielded a total of 1,632 pages of documents that
were initially deemed “potentially responsive.” Id. ¶ 8. Upon review by the HHS FOIA Office,
only 25 pages were deemed fully responsive to Wright’s request, and these were released in full.
Id. The remaining 1,607 pages were deemed unresponsive, meaning they did not contain
relevant information related to adverse reactions to COVID vaccines or related decision memos
and studies. See id. at 3–4. A final decision letter, along with the 25 responsive pages, was sent
to Wright on September 12, 2024. Id. at Ex. B, ECF No. 38-4. This letter communicated the
results of the search and provided the requested documents. Id.; Def.’s Stmt. ¶¶ 10–12.
B. Procedural Background
On October 11, 2023, HHS moved for an eighteen-month stay of FDA’s response to the
request at issue under 5 U.S.C. § 552(a)(6)(C) and Landis v. North American Co., 299 U.S. 248
(1936), because of the unprecedented burden from the court orders in Public Health & Medical
Professionals for Transparency v. FDA, No. 21-cv-1058 (N.D. Tex.) (“PHMPT I”) and Public
Health & Medical Professionals for Transparency v. FDA, No. 22-cv-0915 (N.D. Tex.)
(“PHMPT II”). Def.’s Mot. Extend Stay & Mem. in Supp. (“Mot. Stay”) at 1, ECF No. 48. This
Court granted the eighteen-month stay, but it expired on April 11, 2025. Id. at 3. With the two
cases and additional changes in their circumstances, Defendant seeks to extend the FDA’s stay
Free access — add to your briefcase to read the full text and ask questions with AI
UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
CHRIS WRIGHT, : : Plaintiff, : Civil Action No.: 22-1378 (RC) : v. : Re Document Nos.: 48, 52 : U.S. DEPARTMENT OF HEALTH : AND HUMAN SERVICES, : : Defendant. :
MEMORANDUM OPINION
GRANTING DEFENDANT’S MOTION TO EXTEND STAY; DENYING PLAINTIFF’S MOTION FOR ORDER
I. INTRODUCTION
In this Freedom of Information Act (“FOIA”) action, the U.S. Department of Health and
Human Services (“HHS” or “Defendant”), on behalf of the U.S. Food and Drug Administration
(“FDA” or the “Agency”), seeks to extend the existing stay of the FDA’s further response to the
FOIA request at issue for an additional six months. HHS argues that the FDA is entitled to a stay
because the FDA is under an extraordinary workload that could not have been predicted, and the
FDA has been exercising due diligence in responding to the orders. Proceeding pro se, plaintiff
Chris Wright (“Wright” or “Plaintiff”) contends that because HHS admitted wrongdoing and the
new administration’s attitude towards the public’s rights to public health information differ from
the previous administration, this Court should not grant HHS’s motion to extend stay.
Separately, Wright requested this Court to order President Donald J. Trump’s political
appointees to personally review this case and see whether they want to handle the case
differently than President Joseph R. Biden’s administration. HHS argues that Wright’s motion lacks basis and should be denied. For the foregoing reasons, the Court grants HHS’s motion to
extend stay and denies Wright’s motion for order.
II. FACTUAL AND PROCEDURAL BACKGROUND
A. Factual Background
This action stems from a FOIA request submitted by Wright on November 12, 2021,
seeking several categories of records related to adverse reactions to COVID-19 vaccines.
Specifically, Wright made four requests: (1) “[d]ecision memo(s) or other records regarding
further studies of [Vaccine Adverse Event Reporting System . . . ] COVID vaccine adverse
reaction reports, setting forth the decision(s) and underlying rationale(s)[,]” (2) “[a]ny and all
further studies of adverse reactions to COVID vaccines that have been conducted[,]” (3) “[a]ny
and all records discussing adverse reactions to COVID vaccines after the decision memo(s)[,]”
and (4) [a]ny and all records previously released under same or similar FOIA requests.” Def.’s
Statement of Material Facts Not in Genuine Dispute (“Def.’s Stmt.”) ¶ 1, ECF No. 38-1; Decl. of
Alesia Y. Williams (“Williams Decl.”), Ex. A, ECF No. 38-3. The CDC acknowledged the
request on November 16, 2021, and placed it in its complex processing queue. Def.’s Stmt.
¶¶ 2–3; Decl. of Roger Andoh (“Andoh Decl.”) ¶ 5, ECF No. 38-5. Wright then revised the third
item in the request to specifically target records analyzing mortality as a vaccine adverse
reaction, and he instructed the CDC to use search terms including “death,” “dying,” “dead,”
“kill,” and “murder,” among others. Def.’s Stmt. ¶ 4; Andoh Decl. ¶¶ 17–18.
Following this, the CDC searched records within its Immunization and Safety Office
(“ISO”) and determined the records requested fell within that office’s purview. Andoh Decl. ¶ 6.
The CDC explained that the ISO is responsible for monitoring vaccine safety and therefore was
the appropriate entity to conduct the search. See Def.’s Stmt. ¶ 5; Andoh Decl. ¶ 6. Regarding
2 Item 1, the CDC stated that it does not produce decision memos and therefore had no responsive
documents, but it provided links to standard operating procedures and vaccine safety studies.
See Andoh Decl. ¶ 11; Def.’s Stmt. ¶ 8. For Item 2, the CDC searched and shared links to all
publicly available COVID-19 studies. See Andoh Decl. ¶ 12; Def.’s Stmt. ¶ 8. Following the
revised request for Item 3, the CDC provided links to responsive public records using the
mortality-related search terms. See Andoh Decl. ¶ 19; Def.’s Stmt. ¶ 8. Finally, for Item 4, a
relevant CDC division searched the FOIA inbox, and the search produced thirteen responsive
documents, which were subsequently released to Wright. See Andoh Decl. ¶ 14; Def.’s Stmt.
¶ 8.
Wright then proceeded by filing a motion to compel in July 2023, and in response, the
CDC expanded its search related to Item 1. See Def.’s Stmt. ¶ 6; Andoh Decl. ¶¶ 23–24. From
the expanded search, thirteen pages were partially redacted, six pages were withheld entirely, and
the rest were released in full. Andoh Decl. ¶¶ 23–27; see also CDC Vaughn Index,
ECF No. 38-6. The CDC also asked the Chief Medical Officer and the Incident Manager of the
Coronavirus and Other Respiratory Viruses Division to search their emails and shared drives for
relevant documents, which did not result in any responsive records. Andoh Decl. ¶ 25; Def.’s
Stmt. ¶ 7.
In addition to the CDC’s efforts, HHS itself conducted a search through the Office of the
Chief Information Officer (“OCIO”) within the Office of the Secretary. Def.’s Stmt. ¶ 10;
Williams Decl. at 3, ECF No. 38-2. In response to Wright’s motion to compel, HHS identified
the OCIO as a potential source for responsive records. Id. On April 23, 2024, HHS directed the
OCIO to perform a search of the agency’s email enterprise for emails from key custodians:
Secretary Xavier Becerra, Deputy Secretary Andrea Palm, and Chief of Staff Sean McCluskie.
3 Williams Decl. at 3–4. These individuals were selected based on their likely involvement in
discussions regarding VAERS COVID vaccine adverse reaction reports. Id. ¶ 6. The search
used the terms “Proposal AND COVID AND VAERS” and was limited to emails from
December 14, 2020, through November 11, 2021, which aligned with the time frame specified in
Wright’s FOIA request. Id. ¶ 7. This search yielded a total of 1,632 pages of documents that
were initially deemed “potentially responsive.” Id. ¶ 8. Upon review by the HHS FOIA Office,
only 25 pages were deemed fully responsive to Wright’s request, and these were released in full.
Id. The remaining 1,607 pages were deemed unresponsive, meaning they did not contain
relevant information related to adverse reactions to COVID vaccines or related decision memos
and studies. See id. at 3–4. A final decision letter, along with the 25 responsive pages, was sent
to Wright on September 12, 2024. Id. at Ex. B, ECF No. 38-4. This letter communicated the
results of the search and provided the requested documents. Id.; Def.’s Stmt. ¶¶ 10–12.
B. Procedural Background
On October 11, 2023, HHS moved for an eighteen-month stay of FDA’s response to the
request at issue under 5 U.S.C. § 552(a)(6)(C) and Landis v. North American Co., 299 U.S. 248
(1936), because of the unprecedented burden from the court orders in Public Health & Medical
Professionals for Transparency v. FDA, No. 21-cv-1058 (N.D. Tex.) (“PHMPT I”) and Public
Health & Medical Professionals for Transparency v. FDA, No. 22-cv-0915 (N.D. Tex.)
(“PHMPT II”). Def.’s Mot. Extend Stay & Mem. in Supp. (“Mot. Stay”) at 1, ECF No. 48. This
Court granted the eighteen-month stay, but it expired on April 11, 2025. Id. at 3. With the two
cases and additional changes in their circumstances, Defendant seeks to extend the FDA’s stay
for an additional six months. Id. at 2. Additionally, on May 9, 2025, Wright requested this
Court to order President Trump’s political appointees in the HHS Secretary’s office, the Civil
4 Division at the Justice Department, and in the D.C. U.S. Attorney’s office to review the case.
Pl.’s Mot. for Trump Admin. Review & Mem. in Supp. (“Mot. Order”) at 1, ECF No. 52.
Wright wanted President Trump’s political appointees to review the case and decide whether the
appointees wanted to decide differently than the previous administration’s decision. Id.
III. LEGAL STANDARD
The scope of FOIA gives the district court authority to enjoin an agency from
withholding agency records and order the production of any agency records improperly withheld,
and review the defendant’s actions in the district in which the complainant resides, or has the
defendant’s principal place of business, or in which the agency records are situated, or in the
District of Columbia. See 5 U.S.C. § 552(a)(4)(B). This judicial authority can only be invoked
under the jurisdictional grant conferred by 5 U.S.C. § 552 (a)(4)(B) if an agency has “improperly
withheld agency records.” See Kissinger v. Reps. Comm. for Freedom of the Press, 445 U.S.
136, 150 (1980) (internal quotation marks omitted).
In considering a motion to stay proceedings, the Court will not grant a stay if it would
“unnecessarily delay proceedings” or when consolidating cases would “necessitate a renewed
round of briefing by all parties.” Bell v. Dep't of Def., No. 16-cv-2403, 2018 WL 4637006, at
*18 (D.D.C. Sept. 27, 2018). “A trial court has broad discretion to stay all proceedings in a case
while awaiting the outcome of other proceedings.” Faizi v. Garland, No. 24-839, 2024 WL
5075824, at *2 (D.D.C. Dec. 11, 2024). Thus, courts consider: (1) the injury to the movant if the
litigation proceeds without a stay, (2) the injury to the non-movant if a stay is granted, and (3)
the court’s interest in judicial economy. See Hulley Enters. Ltd. v. Russian Fed’n, 502 F. Supp.
3d 144, 152 (D.D.C. 2020). “[T]he power to stay proceedings is incidental to the power inherent
in every court to control the disposition of the causes on its docket with economy of time and
5 effort for itself, for counsel, and for litigants.” Air Line Pilots Ass’n v. Miller, 523 U.S. 866, 879
n.6 (1998) (alteration in original) (quoting Landis, 299 U.S. at 254–55). Indeed, “[a] trial court
may, with propriety, find it is efficient for its own docket and the fairest course for the parties to
enter a stay of an action before it, pending resolution of independent proceedings which bear
upon the case.” Leyva v. Certified Grocers of Cal., Ltd., 593 F.2d 857, 863 (9th Cir. 1979).
IV. ANALYSIS
Upon consideration of the parties’ submissions—HHS’s motion to extend stay, Wright’s
motion for order, and the accompanying responses—the Court identifies two principal issues that
warrant resolution. First, in resolving the FDA’s motion to stay, the Court must determine
whether HHS had an unreasonably large volume of requests, inadequate resources to resolve the
requests, and a good faith effort in the due diligence of the requests. Second, in resolving
Wright’s motion for order, the Court must address whether it can, or should, order President
Trump’s political appointees to personally review this case and decide whether the appointees
want to handle the matter differently than the previous administration. The Court will address
each of these issues in turn.
A. Motion to Extend Stay
HHS argues that the FDA is entitled to extend the stay for an additional six months
because active litigation in PHMPT I and PHMPT II has imposed “an extraordinary workload”
on FDA, and “FDA [has] experienced a significant reduction in force.” Mot. Stay at 1–2. The
Court agrees.
“Generally, an agency receiving a FOIA request must determine whether to comply with
the request within 20 working days.” See Leadership Conf. on Civ. Rts. v. Gonzales, 404 F.
Supp. 2d 246, 259 (D.D.C. 2005) (citing 5 U.S.C. § 552(a)(6)(A)(i)). If an agency fails to
6 comply with the applicable time limit provisions, the individual who requested access to the
agency’s records is considered to have exhausted all administrative remedies. See 5 U.S.C.
§ 552(a)(6)(C)(i). However, if the Government demonstrates that exceptional circumstances
exist and that the agency is exercising due diligence in processing the request, the court may
retain jurisdiction and grant the agency additional time to complete its review of the records. See
id. This Circuit has held that through 5 U.S.C. § 552(a)(6)(C), Congress intended:
[T]o mean that “exceptional circumstances exist” when an agency, like the [FDA] here, is deluged with a volume of requests for information vastly in excess of that anticipated by Congress, when the existing resources are inadequate to deal with the volume of such requests within the time limits of subsection (6)(A), and when the agency can show that it “is exercising due diligence” in processing the requests.
See Open Am. v. Watergate Special Prosecution Force, 547 F.2d 605, 616 (D.C. Cir. 1976). An
agency’s “good faith effort and due diligence” in responding to lawful FOIA requests—by
processing them “on a first-in, first-out basis,” except when “exceptional need or urgency” is
demonstrated—constitutes compliance with the Act. Id.
The Court finds that exceptional circumstances existed for the FDA within Congress’
interpretation of 5 U.S.C. § 552(a)(6)(C). First, the court-ordered productions in PHMPT I and
PHMPT II—combined with Wright’s requests—created a volume of requests that vastly
exceeded Congress’ expectations. See Gonzales, 404 F. Supp. 2d at 259 (stating that an agency
that received a request for sixteen “projects” was not enough to be considered an exceptional
circumstance). Here, the FDA received a request for “approximately 5.7 million pages of
COVID-19 vaccine-related records” which required FDA to “produce records at rates ranging
from a total of 90,000 to 180,000 pages per month since July 2023.” Mot. Stay at 4. Second, the
FDA did not have the adequate resources to deal with this excess of volume of requests. During
this request period, the FDA experienced a significant reduction in workforce that was
7 unplanned. Id. at 2; see Martin Bros. Constr. v. United States, 176 Fed. Cl. 384 (2025) (holding
exceptional circumstances did not exist when a reduction in workforce was planned). Lastly, the
FDA exercised due diligence throughout the requests. The FDA “implemented a multi-track
process for handling FOIA requests” to combat the large volume of requests. Mot. Stay at 6; see
Democracy Forward Found. v. DOJ, 354 F. Supp. 3d 55, 62 (D.D.C. 2018) (holding that an
agency that implemented a multi-track processing system for FOIA requests had shown
sufficient evidence of due diligence). The new multi-track system would place requests into
“one or more of six queues based on volume, complexity, and/or subject matter and requests in
each queue generally assigned to reviewers for processing on a first-in, first-out basis.” Mot.
Stay at 6. These implementations indicate that even with the immense number of documents that
needed to be processed, the FDA had created a system to best alleviate any inevitable delays.
Thus, the FDA has shown due diligence.
For the reasons stated above, HHS is entitled to a six-month extension of the stay because
the FDA demonstrated that an exceptional circumstance existed and handled the request process
diligently.1 The Court will therefore grant HHS’s motion to extend stay.
B. Motion for Order
Additionally, Wright requested that this Court order President Trump’s political
appointees in the HHS Secretary’s office, the Civil Division at the Justice Department, and in the
D.C. U.S. Attorney’s office to review the case. Mot. Order at 1. Wright argues that the new
1 HHS is also entitled to the extended stay under Landis. In determining whether to grant a stay, the Court considers the injury to the movant if the litigation proceeds without a stay, the injury to the non-movant if a stay is granted, and the Court’s interest in judicial economy. See Hulley, 502 F. Supp. 3d at 152. The FDA is working under limited resources while trying to manage an excess workload, there is no injury to Wright if a stay is granted, and a stay will allow the FDA to properly review and release documents, thus simplifying issues before this Court.
8 administration would handle the matter differently in comparison to the previous administration.
Id. The Court declines to issue such an order.
5 U.S.C. § 552(a)(4)(B) grants a district court jurisdiction to review “de novo” an
agency’s decision to withhold records and empowers courts “to enjoin the agency from
withholding agency records and to order the production of any agency records improperly
withheld from the complainant.” 5 U.S.C. § 552(a)(4)(B). In addition to allowing the district
court to enjoin the agency from withholding records, “[t]he court may assess against the United
States reasonable attorney fees and other litigation costs reasonably incurred in any case under
this section in which the complainant has substantially prevailed.” 5 U.S.C. § 552(a)(4)(E).
The Court finds that Wright is not entitled to the relief he is seeking by requesting this
Court to order President Trump’s political appointees to personally review his case. Under 5
U.S.C. § 552(a)(4), the only recourse that a district court can provide for Wright would be to
enjoin the FDA from withholding the requested documents and assert reasonable attorney fees
and other litigation costs against HHS. See 5 U.S.C. § 552(a)(4)(B), (E). These forms of
recourse would only be available if this Court found the FDA to be improperly withholding the
documents requested by Wright, which this Court has not. See id.; Mem. Op. Granting Def.’s
Mot. Summ. J. at 27, ECF No. 59. Additionally, even if this Court can issue such an order, it
would not do so. Given the constitutionally required separation of powers of co-equal branches
of government, the Court, absent compelling circumstances not present here, will not insert itself
into the internal operations of an executive agency. Wright maintains a First Amendment right
to petition his government. If he wishes to bring his grievances about the handling of this matter
to political appointees within HHS and DOJ, he is free to do so directly.
9 For the reasons stated above, Wright is not entitled to request this Court to order
President Trump’s political appointees to personally review his case and decide whether they
would handle it differently than the previous administration. The Court will therefore deny
Wright’s motion for order.
V. CONCLUSION
For the foregoing reasons, HHS’s Motion to Extend Stay (ECF No. 48) is GRANTED
and Wright’s Motion for Order (ECF No. 52) is DENIED. An order consistent with this
Memorandum Opinion is separately and contemporaneously issued.
Dated: July 31, 2025 RUDOLPH CONTRERAS United States District Judge